Developing a new treatment for immune thrombocytopenia using a specialized enzyme
Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
This study is testing a new treatment for people with immune thrombocytopenia (ITP) that uses a specially designed enzyme to help reduce harmful antibodies and improve platelet counts, aiming to provide a safer and more effective option than what’s currently available.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cyrus Biotechnology, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11069861 on NIH RePORTER |
What this research studies
This research focuses on creating a novel treatment for immune thrombocytopenia (ITP), an autoimmune disorder characterized by low platelet counts due to IgG autoantibodies. The approach involves engineering a bacterial enzyme, IdeS, to effectively deplete these harmful antibodies while minimizing side effects. By utilizing advanced protein design techniques, the researchers aim to enhance the enzyme's effectiveness and longevity in the body. Patients may benefit from a more effective and safer treatment option compared to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with immune thrombocytopenia who have not responded adequately to existing treatments.
Not a fit: Patients with other forms of thrombocytopenia not related to IgG autoantibodies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and durable treatment option for patients suffering from immune thrombocytopenia.
How similar studies have performed: Previous research has shown promise in using similar enzymatic approaches for antibody depletion, indicating potential for success in this novel application.
Where this research is happening
Seattle, United States
- Cyrus Biotechnology, INC. — Seattle, United States (Active)
Researchers
- Principal investigator: Procko, Erik — Cyrus Biotechnology, INC.
- Study coordinator: Procko, Erik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.